RET and non-small cell lung carcinoma: Median OS was not reached; the 12-month survival rate was 80.9% (95% CI, 74.9-85.6).<h4>Conclusions</h4>Real-world data showed selpercatinib to be effective in patients with RET fusion-positive NSCLC in Japan, with a favorable safety profile and no new safety concerns.